Cirrhosis and portal hypertension may be associated with pulmonary hypertension and pulmonary dysfunction. However, morphological pulmonary vascular lesions in patients with cirrhosis have not been well characterized morphometrically. We morphometrically evaluated pulmonary vessels in liver transpla
Audiometric changes in patients undergoing liver transplantation using distinct immunosuppressive protocols
✍ Scribed by Maria Elena Fortes; Cláudio Augusto Marroni; Pedro Luis Coser; Carlos Abaeté de los Santos
- Publisher
- John Wiley and Sons
- Year
- 2008
- Tongue
- English
- Weight
- 73 KB
- Volume
- 14
- Category
- Article
- ISSN
- 1527-6465
- DOI
- 10.1002/lt.21385
No coin nor oath required. For personal study only.
✦ Synopsis
The aim of the study was to disclose a possible association of hearing defects with the use of either cyclosporin (CyA) or tacrolimus (FK-506) in patients undergoing liver transplantation (LT). Pure-tone audiometry (PTA) was performed in the same 42 patients before and after LT. Audiometric frequencies recorded ranged from 250 to 8000 Hz. Patients were divided into 2 groups according to the use of CyA (n ϭ 18) or FK-506 (n ϭ 24). We used Kolmogorov-Smirnov and subsequently Student t test, nonparametric Wilcoxon signed-rank test, and Mann-Whitney test for statistical analysis. Significance was achieved when P Յ 0.05. There was a statistically significant change in PTA results, occurring as decreased hearing perception, especially in high frequencies (4000, 6000, and 8000 Hz), in both ears of patients undergoing LT and receiving FK-506. Audiometric changes were not perceived pre-and posttransplantation in patients using CyA, except in the right ear, in the 3000-Hz range. In conclusion, LT patients presented worsening of hearing patterns after undergoing transplantation. The defect was significantly more accentuated in the high-frequency tones, particularly in individuals using FK-506 as the immunosuppressive regimen.
📜 SIMILAR VOLUMES
Studies have suggested that the use of hepatitis C virus (HCV)-positive (HCV+) donor allografts has no impact on survival. However, no studies have examined the effect that HCV+ donor histology has upon recipient and graft survival. We evaluated the clinical outcome and impact of histological featur
Recurrent hepatitis B virus (HBV) infection remains a major cause of morbidity and mortality after liver transplantation. Recently, antiviral therapy, such as lamivudine, has become available for prophylaxis against HBV reactivation posttransplantation and for the treatment of HBV recurrent disease.